Cytokinetics Sees Omecamtiv Potential In Certain Heart Failure Patients
The Company And Amgen Continue To Analyze GALACTIC-HF Results
Detailed data for omecamtiv mecarbil at AHA show a slim overall benefit, but Cytokinetics highlighted its effects in sicker patients and investigators emphasized the drug’s impact on reduced hospitalizations.
You may also be interested in...
Upcoming US FDA decisions could bring breakthrough-designated approvals for BI/Lilly’s Jardiance in heart failure with preserved ejection fraction and BMS’ mavacamten in hypertrophic cardiomyopathy, while Cytokinetics bids to bring a new mechanism the busy heart failure with reduced ejection fraction space and earns a BTD in HCM.
Five notable studies are expected to report top-line data in the first quarter. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the major catalysts likely to kick off the year, including in heart failure and wet AMD.
The REDWOOD-HCM study showed early, sustained efficacy and no serious adverse events with a drug Cytokinetics designed to be superior to mavacamten, a drug it spun out via BMS-acquired MyoKardia.